Concurrent paclitaxel, capecitabine, mitomycin C and pelvic radiation therapy for patients with squamous cell anal carcinoma

Gordeev, S. S.; Расулов, А. О.; Gorbounova, Vera; Ткачев, С. И.; Glebovskaya, V. V.; Fedyanin, Mikhail; Besova, N.; Surayeva, Yulia E

doi:10.1007/s00280-017-3408-4

Cited by 5 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Concurrent chemo and radiation therapies (CRT) is a standard treatment for many solid tumors, especially locally advanced cancers [67]. Many chemotherapeutants, such as cisplatin, docetaxel, and 5-fluorouracil, have been identified as radiosensitizers to improve local control and survival rates, while potentially eradicating distant micrometastatic disease [68][69][70]. However, concurrent chemoradiation causes more serious side effects, compared with therapy alone or sequential RT and chemotherapy [71].…”

Section: Nanomaterials For Combined Chemotherapy and Rtmentioning

confidence: 99%

See 1 more Smart Citation

Advances of Nanomedicine in Radiotherapy

et al. 2021

View full text Add to dashboard Cite

Radiotherapy (RT) remains one of the current main treatment strategies for many types of cancer. However, how to improve RT efficiency while reducing its side effects is still a large challenge to be overcome. Advancements in nanomedicine have provided many effective approaches for radiosensitization. Metal nanoparticles (NPs) such as platinum-based or hafnium-based NPs are proved to be ideal radiosensitizers because of their unique physicochemical properties and high X-ray absorption efficiency. With nanoparticles, such as liposomes, bovine serum albumin, and polymers, the radiosensitizing drugs can be promoted to reach the tumor sites, thereby enhancing anti-tumor responses. Nowadays, the combination of some NPs and RT have been applied to clinical treatment for many types of cancer, including breast cancer. Here, as well as reviewing recent studies on radiotherapy combined with inorganic, organic, and biomimetic nanomaterials for oncology, we analyzed the underlying mechanisms of NPs radiosensitization, which may contribute to exploring new directions for the clinical translation of nanoparticle-based radiosensitizers.

show abstract

Section: Nanomaterials For Combined Chemotherapy and Rtmentioning

confidence: 99%

“…It has been found that some traditional chemotherapy drugs can serve as radiosensitizers to increase the efficiency of RT through different mechanisms [68][69][70]. For example, paclitaxel (PTX) can arrest cells at the G2/M phase, which is more sensitive to radiation [68].…”

Section: The Clinical Translation Of Nanomaterials As Radiosensitizersmentioning

confidence: 99%

Advances of Nanomedicine in Radiotherapy

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Заболевание преимущественно диагностируют в локализованной или местно-распространенной форме, когда имеются возможности эффективного радикального лечения. Корректное построение врачебной тактики может обеспечить 5-летнюю выживаемость у 80-90 % пациентов с сохранением высокого качества жизни и полноценной трудоспособности [7,[9][10][11]. Нарушение плана лечения приводит к высокой частоте инвалидизации, повышению частоты выполнения калечащих операций и более высокой смертности.…”

Section: ' 2020unclassified

role of telehealth services in the treatment of rare disease: analysis of 1 year of work on the example of anal cancer

Гордеев

Федянин

Глазкова

et al. 2020

Onkol. koloproktol.

Self Cite

View full text Add to dashboard Cite

Objective: to assess the potential need for telehealth consultations in regions for the treatment of patients diagnosed with anal cancer and to analyze the most common treatment errors. Materials and methods. We analyzed telehealth consultations provided for 3 Federal districts between April 2019 and April 2020. The following parameters were evaluated: the ratio between the predicted need for telehealth consultations and the real number of requests, the number of medical errors in patients who had already undergone first and / or subsequent treatment stages (according to relevant clinical guidelines). Results. Fifteen telehealth consultations were provided during this year: 13 of them (86.7 %) for disease progression or complications and 2 of them (13.3 %) to determine the initial treatment strategy. Treatment errors were registered in 11 out of 13 cases (84.6 %). The predicted need based on the population size was 565 consultations per year; the predicted need based on the real number of patients visited cancer clinics was 81 consultations. Conclusions. We found many significant errors in treatment regimens of patients with squamous cell anal carcinoma. Wider use of telehealth consultations with Federal centers will ensure the correct choice of the initial treatment strategy.

show abstract

“…Some patients will, however, not be eligible for platinum‐based treatment, and alternative regimens are relevant. Paclitaxel‐based chemotherapy has shown activity in both the chemotherapy‐naive and chemo‐refractory setting in SCCA, 9,10 and the combination regimen of Paclitaxel and Capecitabine has been investigated as a nonplatinum‐based option for head and neck cancer with relevant efficacy and moderate toxicity reported 11 . Theoretically, the combination of Taxanes and Capecitabine also offers reasonable predictable efficacy due to the given mechanism of action, and previous studies have found a synergy in vivo, thought to be caused by Taxane up‐regulating dThdPase and thereby enhancing the efficacy of Capecitabine 12,13 …”

Section: Introductionmentioning

confidence: 99%

Nonplatinum‐based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population‐based Danish anal cancer group study

et al. 2021

View full text Add to dashboard Cite

Background First‐line platinum‐based therapy for advanced squamous cell carcinomas of the anal canal (SCCA) implies a risk of substantial side effects, and data on second‐line treatment options are limited. Paclitaxel and Capecitabine are a well‐known regimen with a moderate toxicity profile, but its efficacy has not been evaluated. Methods We conducted a retrospective study using Danish Hospital Registers of patients treated with Paclitaxel and Capecitabine for inoperable, recurrent, or advanced metastatic SCCA in Denmark, between January 2000 and July 2018. Results A total of 52 patients met the eligibility criteria. Median age was 60.7 years (range 42–83). Efficacy was observed, with an overall response rate in patients receiving first‐line (N = 28) and second‐line (N = 23) Paclitaxel and Capecitabine of 39.3% (2 with complete responses) and 17.4%, respectively. Median progression‐free survival (PFS) was 4.5 months (95% CI 3.3–5.9) and 3.8 months (95% CI 2.4–5.5) with OS of 6.7 months (95% CI 5.9–8.5) and 5.9 months (95% CI 3.9–14), respectively. Performance status ≥2 and neutrophil to lymphocyte ratio ≥4 were significantly associated with a short PFS. Conclusion This study recognizes Paclitaxel and Capecitabine as a potential regimen for advanced SCCA, when recommended first‐line therapy is not feasible or as a potential second‐line treatment after failure of platinum‐based chemotherapy.

show abstract

Concurrent paclitaxel, capecitabine, mitomycin C and pelvic radiation therapy for patients with squamous cell anal carcinoma

Abstract: Investigated treatment scheme is feasible despite high toxicity profile, and may be beneficial for patients with advanced SCAC. Further research is warranted.

Cited by 5 publications

References 30 publications

Advances of Nanomedicine in Radiotherapy

Advances of Nanomedicine in Radiotherapy

role of telehealth services in the treatment of rare disease: analysis of 1 year of work on the example of anal cancer

Nonplatinum‐based therapy with Paclitaxel and Capecitabine for advanced squamous cell carcinomas of the anal canal: A population‐based Danish anal cancer group study

Contact Info

Product

Resources

About